☰ 🔍
🖊️Ask a Question
Electrical Engineering

What is true of tamoxifen: A. It can induce endometrial proliferation in postmenopausal women B. It exerts antiestrogenic activity in bone C. It raises LDL-cholesterol levels D. It is ineffective in estrogen receptor-negative breast cancer

by 0 views
What is true of tamoxifen:
A. It can induce endometrial proliferation in
postmenopausal women
B. It exerts antiestrogenic activity in bone
C. It raises LDL-cholesterol levels
D. It is ineffective in estrogen receptor-negative
breast cancer
0 like 0 dislike

1 Answer

by
A. It can induce endometrial proliferation in
postmenopausal women
0 like 0 dislike

Related questions

by trupti chikram asked Jul 22, 2021 0 views
The following is true of raloxifene except: A. It acts as an estrogen agonist in bone B. It exerts estrogen antagonistic action on endometrium C. It increases risk of developing breast cancer D. It can induce/aggravate menopausal hot flushes

The following is true of raloxifene except: A. It acts as an estrogen agonist in bone B. It exerts estrogen antagonistic action on endometrium C. It increases risk of developing breast cancer D. It can induce/aggravate menopausal hot flushes
Answer : C. It has additional androgenic acitivity...

View solution
0 like 0 dislike
1 answer
by trupti chikram asked Jul 22, 2021 0 views
The following effect(s) of tamoxifen citrate indicate(s) that it possesses tissue specific estrogenic action as well: A. Inhibition of breast cancer cells B. Endometrial proliferation C. Hot flushes in premenopausal women D. All of the above

The following effect(s) of tamoxifen citrate indicate(s) that it possesses tissue specific estrogenic action as well: A. Inhibition of breast cancer cells B. Endometrial proliferation C. Hot flushes in premenopausal women D. All of the above
Answer : B. Endometrial proliferation...

View solution
0 like 0 dislike
1 answer
by trupti chikram asked Jul 22, 2021 0 views
Estrogen therapy in postmenopausal women has been implicated in increasing the risk of the following disorders except: A. Gall stones B. Osteoporosis C. Endometrial carcinoma D. Breast cancer

Estrogen therapy in postmenopausal women has been implicated in increasing the risk of the following disorders except: A. Gall stones B. Osteoporosis C. Endometrial carcinoma D. Breast cancer
Answer : B. Osteoporosis...

View solution
0 like 0 dislike
1 answer
by trupti chikram asked Jul 22, 2021 0 views
Which of the following is a selective estrogen receptor modulator that improves bone mineral density in postmenopausal women: A. Clomiphene citrate B. Raloxifene C. Ormeloxifene D. Alendronate

Which of the following is a selective estrogen receptor modulator that improves bone mineral density in postmenopausal women: A. Clomiphene citrate B. Raloxifene C. Ormeloxifene D. Alendronate
Answer : B. Raloxifene...

View solution
0 like 0 dislike
1 answer
by trupti chikram asked Jul 25, 2021 0 views
What is true of docetaxel: A. It is used as a reserve drug for refractory breast and ovarian cancer B. It is a selective estrogen receptor modulator used for breast cancer C. It is effective only in estrogen receptor positive breast cancer D. Both 'B' and 'C' are correct

What is true of docetaxel: A. It is used as a reserve drug for refractory breast and ovarian cancer B. It is a selective estrogen receptor modulator used for breast cancer C. It is effective only in estrogen receptor positive breast cancer D. Both 'B' and 'C' are correct
Answer : A. It is used as a reserve drug for refractory breast and ovarian cancer...

View solution
0 like 0 dislike
1 answer

50.5k questions

47.1k answers

240 comments

7.0k users

© 2025 Question Answer